AGW0 Stock Chart & Stats
€0.21
€0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range€0.10 - €0.76
Previous CloseN/A
VolumeN/A
Average Volume (3M)76.00
Market Cap
€1.93M
Enterprise Value€3.70
Total Cash (Recent Filing)€210.03K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding8,923,237
10 Day Avg. Volume16
30 Day Avg. Volume76
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.15
Revenue Forecast (FY)€695.94K
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure reduces fixed interest obligations and financial distress risk, giving management flexibility to allocate equity or cash to R&D and commercialization. Over 2–6 months this structural strength improves runway options and reduces refinancing pressure.
Narrowing Net LossesA sustained reduction in annual net losses signals improving cost discipline and operational efficiency. If maintained, this trend lowers future capital needs and increases the probability the firm can reach break-even once revenue begins, supporting longer-term viability.
Focus On Digital Therapeutics For Mental/neurological HealthOperating in digital therapeutics taps a durable structural tailwind: growing demand for mental and neurological care, scalable software delivery, and potential for recurring revenue. This sector alignment supports high long-term margin potential if products achieve adoption.
Bears Say
Zero Reported RevenueNo reported revenue means the company has not yet proven commercial product-market fit. Without recurring sales, the business cannot validate pricing, scale operations, or self-fund growth, leaving long-term viability dependent on successful commercialization or new funding.
Persistent Negative Operating And Free Cash FlowContinued negative cash flow forces reliance on external capital, which risks dilution and constrains investment in clinical validation or go-to-market activities. Even with improvement, ongoing burn raises funding uncertainty over a multi-month horizon.
Very Small Operating Scale (5 Employees)A tiny headcount limits capacity for product development, regulatory work, partnerships, and commercialization. Scale constraints make it harder to execute multi-faceted clinical and go-to-market plans, delaying revenue generation and increasing execution risk.
Grey Matters Health News
AGW0 FAQ
What was Grey Matters Health’s price range in the past 12 months?
Grey Matters Health lowest stock price was €0.10 and its highest was €0.76 in the past 12 months.
What is Grey Matters Health’s market cap?
Grey Matters Health’s market cap is €1.93M.
When is Grey Matters Health’s upcoming earnings report date?
Grey Matters Health’s upcoming earnings report date is Dec 18, 2026 which is in 136 days.
How were Grey Matters Health’s earnings last quarter?
Grey Matters Health released its earnings results on Jul 29, 2026. The company reported -€0.08 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Grey Matters Health overvalued?
According to Wall Street analysts Grey Matters Health’s price is currently Undervalued.
Does Grey Matters Health pay dividends?
Grey Matters Health does not currently pay dividends.
What is Grey Matters Health’s EPS estimate?
Grey Matters Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Grey Matters Health have?
Grey Matters Health has 8,923,237 shares outstanding.
What happened to Grey Matters Health’s price movement after its last earnings report?
Grey Matters Health reported an EPS of -€0.08 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.484%.
Which hedge fund is a major shareholder of Grey Matters Health?
Currently, no hedge funds are holding shares in DE:AGW0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Grey Matters Health
Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Health Inc. and changed its name to Grey Matters Health Inc. in April 2026. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Technical Analysis
Appili Therapeutics Inc Class A
―
Rakovina Therapeutics Inc
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―